Celmatix
Celmatix Therapeutics, based in New York City and Cambridge, MA, is at the forefront of pioneering new therapies for women's health, specifically focusing on ovarian health and its critical role beyond reproduction. The company is dedicated to addressing high unmet needs in women's health through innovative drug programs targeting conditions such as endometriosis, polycystic ovary syndrome (PCOS), and ovarian aging.
With a robust pipeline of groundbreaking therapies and a recent award of $35 million from the Advanced Research Projects Agency for Health (ARPA-H), Celmatix is committed to transforming women's health by developing therapeutics that enhance the quality of life for women throughout their lifespans. Their research emphasizes the unique biology of women, aiming to create effective treatments that address the physiological challenges they face as they age.
Generated from the website